- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The PD-1/PD-L1 Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global PD-1/PD-L1 Immunotherapy size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global PD-1/PD-L1 Immunotherapy market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
PD-1/PD-L1 Immunotherapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
PD-1 Inhibitors
PD-L1 Inhibitors
Market segment by Application can be divided into
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
The key market players for global PD-1/PD-L1 Immunotherapy market are listed below:
AstraZeneca Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe PD-1/PD-L1 Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PD-1/PD-L1 Immunotherapy, with price, sales, revenue and global market share of PD-1/PD-L1 Immunotherapy in 2018 and 2019.
Chapter 3, the PD-1/PD-L1 Immunotherapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1/PD-L1 Immunotherapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and PD-1/PD-L1 Immunotherapy market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe PD-1/PD-L1 Immunotherapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 PD-1/PD-L1 Immunotherapy Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global PD-1/PD-L1 Immunotherapy Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global PD-1/PD-L1 Immunotherapy Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Global PD-1/PD-L1 Immunotherapy Market Size & Forecast
1.4.1 Global PD-1/PD-L1 Immunotherapy Sales in Value (2016-2026))
1.4.2 Global PD-1/PD-L1 Immunotherapy Sales in Volume (2016-2026)
1.4.3 Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2026) & (US$/Unit)
1.5 Global PD-1/PD-L1 Immunotherapy Production Capacity Analysis
1.5.1 Global PD-1/PD-L1 Immunotherapy Total Production Capacity (2016-2026)
1.5.2 Global PD-1/PD-L1 Immunotherapy Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 PD-1/PD-L1 Immunotherapy Market Drivers
1.6.2 PD-1/PD-L1 Immunotherapy Market Restraints
1.6.3 PD-1/PD-L1 Immunotherapy Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca Plc
2.1.1 AstraZeneca Plc Details
2.1.2 AstraZeneca Plc Major Business
2.1.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product and Services
2.1.4 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 BeiGene, Ltd.
2.2.1 BeiGene, Ltd. Details
2.2.2 BeiGene, Ltd. Major Business
2.2.3 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product and Services
2.2.4 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Bristol-Myers Squibb Company
2.3.1 Bristol-Myers Squibb Company Details
2.3.2 Bristol-Myers Squibb Company Major Business
2.3.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product and Services
2.3.4 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
2.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Details
2.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Major Business
2.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product and Services
2.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Eli Lilly & Company
2.5.1 Eli Lilly & Company Details
2.5.2 Eli Lilly & Company Major Business
2.5.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product and Services
2.5.4 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 F. Hoffmann-La Roche Ltd
2.6.1 F. Hoffmann-La Roche Ltd Details
2.6.2 F. Hoffmann-La Roche Ltd Major Business
2.6.3 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product and Services
2.6.4 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 GlaxoSmithKline plc
2.7.1 GlaxoSmithKline plc Details
2.7.2 GlaxoSmithKline plc Major Business
2.7.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product and Services
2.7.4 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Innovent Biologics, Inc.
2.8.1 Innovent Biologics, Inc. Details
2.8.2 Innovent Biologics, Inc. Major Business
2.8.3 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product and Services
2.8.4 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Jiangsu HengRui Medicine Co., Ltd.
2.9.1 Jiangsu HengRui Medicine Co., Ltd. Details
2.9.2 Jiangsu HengRui Medicine Co., Ltd. Major Business
2.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product and Services
2.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Merck & Co., Inc.
2.10.1 Merck & Co., Inc. Details
2.10.2 Merck & Co., Inc. Major Business
2.10.3 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product and Services
2.10.4 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Novartis AG
2.11.1 Novartis AG Details
2.11.2 Novartis AG Major Business
2.11.3 Novartis AG PD-1/PD-L1 Immunotherapy Product and Services
2.11.4 Novartis AG PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 Pfizer Inc.
2.12.1 Pfizer Inc. Details
2.12.2 Pfizer Inc. Major Business
2.12.3 Pfizer Inc. PD-1/PD-L1 Immunotherapy Product and Services
2.12.4 Pfizer Inc. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Regeneron Pharmaceuticals Inc.
2.13.1 Regeneron Pharmaceuticals Inc. Details
2.13.2 Regeneron Pharmaceuticals Inc. Major Business
2.13.3 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product and Services
2.13.4 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Sanofi S.A.
2.14.1 Sanofi S.A. Details
2.14.2 Sanofi S.A. Major Business
2.14.3 Sanofi S.A. PD-1/PD-L1 Immunotherapy Product and Services
2.14.4 Sanofi S.A. PD-1/PD-L1 Immunotherapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 PD-1/PD-L1 Immunotherapy Sales by Manufacturer
3.1 Global PD-1/PD-L1 Immunotherapy Sales in Volume by Manufacturer (2019-2021e)
3.2 Global PD-1/PD-L1 Immunotherapy Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in PD-1/PD-L1 Immunotherapy
3.4 Market Concentration Rate
3.4.1 Top 3 PD-1/PD-L1 Immunotherapy Manufacturer Market Share
3.4.2 Top 6 PD-1/PD-L1 Immunotherapy Manufacturer Market Share
3.5 Global PD-1/PD-L1 Immunotherapy Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and PD-1/PD-L1 Immunotherapy Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global PD-1/PD-L1 Immunotherapy Market Size by Region
4.1.1 Global PD-1/PD-L1 Immunotherapy Sales in Volume by Region (2016-2026)
4.1.2 Global PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2026)
4.2 North America PD-1/PD-L1 Immunotherapy Revenue (2016-2026)
4.3 Europe PD-1/PD-L1 Immunotherapy Revenue (2016-2026)
4.4 Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue (2016-2026)
4.5 South America PD-1/PD-L1 Immunotherapy Revenue (2016-2026)
4.6 Middle East and Africa PD-1/PD-L1 Immunotherapy Revenue (2016-2026)
5 Market Segment by Type
5.1 Global PD-1/PD-L1 Immunotherapy Sales in Volume by Type (2016-2026)
5.2 Global PD-1/PD-L1 Immunotherapy Revenue by Type (2016-2026)
5.3 Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global PD-1/PD-L1 Immunotherapy Sales in Volume by Application (2016-2026)
6.2 Global PD-1/PD-L1 Immunotherapy Revenue by Application (2016-2026)
6.3 Global PD-1/PD-L1 Immunotherapy Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America PD-1/PD-L1 Immunotherapy Sales by Type (2016-2026)
7.2 North America PD-1/PD-L1 Immunotherapy Sales by Application (2016-2026)
7.3 North America PD-1/PD-L1 Immunotherapy Market Size by Country
7.3.1 North America PD-1/PD-L1 Immunotherapy Sales in Volume by Country (2016-2026)
7.3.2 North America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe PD-1/PD-L1 Immunotherapy Sales by Type (2016-2026)
8.2 Europe PD-1/PD-L1 Immunotherapy Sales by Application (2016-2026)
8.3 Europe PD-1/PD-L1 Immunotherapy Market Size by Country
8.3.1 Europe PD-1/PD-L1 Immunotherapy Sales in Volume by Country (2016-2026)
8.3.2 Europe PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Type (2016-2026)
9.2 Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Application (2016-2026)
9.3 Asia-Pacific PD-1/PD-L1 Immunotherapy Market Size by Region
9.3.1 Asia-Pacific PD-1/PD-L1 Immunotherapy Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America PD-1/PD-L1 Immunotherapy Sales by Type (2016-2026)
10.2 South America PD-1/PD-L1 Immunotherapy Sales by Application (2016-2026)
10.3 South America PD-1/PD-L1 Immunotherapy Market Size by Country
10.3.1 South America PD-1/PD-L1 Immunotherapy Sales in Volume by Country (2016-2026)
10.3.2 South America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Type (2016-2026)
11.2 Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Application (2016-2026)
11.3 Middle East & Africa PD-1/PD-L1 Immunotherapy Market Size by Country
11.3.1 Middle East & Africa PD-1/PD-L1 Immunotherapy Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 PD-1/PD-L1 Immunotherapy Typical Distributors
12.3 PD-1/PD-L1 Immunotherapy Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global PD-1/PD-L1 Immunotherapy Revenue by Type, (USD Million), 2021-2026
Table 2. Global PD-1/PD-L1 Immunotherapy Revenue by Application, (USD Million), 2021-2026
Table 3. AstraZeneca Plc Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Plc Major Business
Table 5. AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product and Services
Table 6. AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. BeiGene, Ltd. Basic Information, Manufacturing Base and Competitors
Table 8. BeiGene, Ltd. Major Business
Table 9. BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product and Services
Table 10. BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 12. Bristol-Myers Squibb Company Major Business
Table 13. Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product and Services
Table 14. Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Basic Information, Manufacturing Base and Competitors
Table 16. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Major Business
Table 17. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product and Services
Table 18. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Eli Lilly & Company Basic Information, Manufacturing Base and Competitors
Table 20. Eli Lilly & Company Major Business
Table 21. Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product and Services
Table 22. Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 24. F. Hoffmann-La Roche Ltd Major Business
Table 25. F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product and Services
Table 26. F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 28. GlaxoSmithKline plc Major Business
Table 29. GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product and Services
Table 30. GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Innovent Biologics, Inc. Major Business
Table 33. Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product and Services
Table 34. Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Jiangsu HengRui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 36. Jiangsu HengRui Medicine Co., Ltd. Major Business
Table 37. Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product and Services
Table 38. Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 40. Merck & Co., Inc. Major Business
Table 41. Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product and Services
Table 42. Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 44. Novartis AG Major Business
Table 45. Novartis AG PD-1/PD-L1 Immunotherapy Product and Services
Table 46. Novartis AG PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 48. Pfizer Inc. Major Business
Table 49. Pfizer Inc. PD-1/PD-L1 Immunotherapy Product and Services
Table 50. Pfizer Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Regeneron Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 52. Regeneron Pharmaceuticals Inc. Major Business
Table 53. Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product and Services
Table 54. Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 56. Sanofi S.A. Major Business
Table 57. Sanofi S.A. PD-1/PD-L1 Immunotherapy Product and Services
Table 58. Sanofi S.A. PD-1/PD-L1 Immunotherapy Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Global PD-1/PD-L1 Immunotherapy Sales by Manufacturer (2019-2021e) & (Units)
Table 60. Global PD-1/PD-L1 Immunotherapy Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 61. Market Position of Manufacturers in PD-1/PD-L1 Immunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 62. Global PD-1/PD-L1 Immunotherapy Production Capacity by Company, (Units): 2020 VS 2021
Table 63. Head Office and PD-1/PD-L1 Immunotherapy Production Site of Key Manufacturer
Table 64. PD-1/PD-L1 Immunotherapy New Entrant and Capacity Expansion Plans
Table 65. PD-1/PD-L1 Immunotherapy Mergers & Acquisitions in the Past Five Years
Table 66. Global PD-1/PD-L1 Immunotherapy Sales by Region (2016-2021e) & (Units)
Table 67. Global PD-1/PD-L1 Immunotherapy Sales by Region (2021-2026) & (Units)
Table 68. Global PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2021e) & (USD Million)
Table 69. Global PD-1/PD-L1 Immunotherapy Revenue by Region (2021-2026) & (USD Million)
Table 70. Global PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 71. Global PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 72. Global PD-1/PD-L1 Immunotherapy Revenue by Type (2016-2021e) & (USD Million)
Table 73. Global PD-1/PD-L1 Immunotherapy Revenue by Type (2021-2026) & (USD Million)
Table 74. Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2021e) & (US$/Unit)
Table 75. Global PD-1/PD-L1 Immunotherapy Price by Type (2021-2026) & (US$/Unit)
Table 76. Global PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 77. Global PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 78. Global PD-1/PD-L1 Immunotherapy Revenue by Application (2016-2021e) & (USD Million)
Table 79. Global PD-1/PD-L1 Immunotherapy Revenue by Application (2021-2026) & (USD Million)
Table 80. Global PD-1/PD-L1 Immunotherapy Price by Application (2016-2021e) & (US$/Unit)
Table 81. Global PD-1/PD-L1 Immunotherapy Price by Application (2021-2026) & (US$/Unit)
Table 82. North America PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021e) & (Units)
Table 83. North America PD-1/PD-L1 Immunotherapy Sales by Country (2021-2026) & (Units)
Table 84. North America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021e) & (USD Million)
Table 85. North America PD-1/PD-L1 Immunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 86. North America PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 87. North America PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 88. North America PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 89. North America PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 90. Europe PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021e) & (Units)
Table 91. Europe PD-1/PD-L1 Immunotherapy Sales by Country (2021-2026) & (Units)
Table 92. Europe PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021e) & (USD Million)
Table 93. Europe PD-1/PD-L1 Immunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 94. Europe PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 95. Europe PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 96. Europe PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 97. Europe PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 98. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Region (2016-2021e) & (Units)
Table 99. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Region (2021-2026) & (Units)
Table 100. Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue by Region (2016-2021e) & (USD Million)
Table 101. Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue by Region (2021-2026) & (USD Million)
Table 102. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 103. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 104. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 105. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 106. South America PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021e) & (Units)
Table 107. South America PD-1/PD-L1 Immunotherapy Sales by Country (2021-2026) & (Units)
Table 108. South America PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021e) & (USD Million)
Table 109. South America PD-1/PD-L1 Immunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 110. South America PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 111. South America PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 112. South America PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 113. South America PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 114. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Country (2016-2021e) & (Units)
Table 115. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Country (2021-2026) & (Units)
Table 116. Middle East & Africa PD-1/PD-L1 Immunotherapy Revenue by Country (2016-2021e) & (USD Million)
Table 117. Middle East & Africa PD-1/PD-L1 Immunotherapy Revenue by Country (2021-2026) & (USD Million)
Table 118. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Type (2016-2021e) & (Units)
Table 119. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Type (2021-2026) & (Units)
Table 120. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Application (2016-2021e) & (Units)
Table 121. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales by Application (2021-2026) & (Units)
Table 122. Direct Channel Pros & Cons
Table 123. Indirect Channel Pros & Cons
Table 124. PD-1/PD-L1 Immunotherapy Typical Distributors
Table 125. PD-1/PD-L1 Immunotherapy Typical Customers
List of Figures
Figure 1. PD-1/PD-L1 Immunotherapy Picture
Figure 2. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Type in 2020
Figure 3. PD-1 Inhibitors
Figure 4. PD-L1 Inhibitors
Figure 5. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Application in 2020
Figure 6. Non-Small Cell Lung Cancer
Figure 7. Esophageal Cancer
Figure 8. Urothelial Carcinoma
Figure 9. Hepatocellular Carcinoma
Figure 10. Small Cell Lung Cancer
Figure 11. Others
Figure 12. Global PD-1/PD-L1 Immunotherapy Market Size, (USD Million) & (Units): 2020 VS 2021 VS 2026
Figure 13. Global PD-1/PD-L1 Immunotherapy Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global PD-1/PD-L1 Immunotherapy Sales (2016-2026) & (Units)
Figure 15. Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2026) & (US$/Unit)
Figure 16. Global PD-1/PD-L1 Immunotherapy Production Capacity (2016-2026) & (Units)
Figure 17. Global PD-1/PD-L1 Immunotherapy Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. PD-1/PD-L1 Immunotherapy Market Drivers
Figure 19. PD-1/PD-L1 Immunotherapy Market Restraints
Figure 20. PD-1/PD-L1 Immunotherapy Market Trends
Figure 21. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Manufacturer in 2020
Figure 22. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Manufacturer in 2020
Figure 23. PD-1/PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 PD-1/PD-L1 Immunotherapy Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 PD-1/PD-L1 Immunotherapy Manufacturer (Revenue) Market Share in 2020
Figure 26. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2026)
Figure 27. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Region (2016-2026)
Figure 28. North America PD-1/PD-L1 Immunotherapy Revenue (2016-2026) & (USD Million)
Figure 29. Europe PD-1/PD-L1 Immunotherapy Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue (2016-2026) & (USD Million)
Figure 31. South America PD-1/PD-L1 Immunotherapy Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa PD-1/PD-L1 Immunotherapy Revenue (2016-2026) & (USD Million)
Figure 33. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2026)
Figure 34. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Type (2016-2026)
Figure 35. Global PD-1/PD-L1 Immunotherapy Price by Type (2016-2026) & (US$/Unit)
Figure 36. Global PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 37. Global PD-1/PD-L1 Immunotherapy Revenue Market Share by Application (2016-2026)
Figure 38. Global PD-1/PD-L1 Immunotherapy Price by Application (2016-2026) & (US$/Unit)
Figure 39. North America PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2026)
Figure 40. North America PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 41. North America PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2026)
Figure 42. North America PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2026)
Figure 43. United States PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2026)
Figure 47. Europe PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 48. Europe PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2026)
Figure 49. Europe PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2026)
Figure 50. Germany PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific PD-1/PD-L1 Immunotherapy Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific PD-1/PD-L1 Immunotherapy Revenue Market Share by Region (2016-2026)
Figure 59. China PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2026)
Figure 66. South America PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 67. South America PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2026)
Figure 68. South America PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2026)
Figure 69. Brazil PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa PD-1/PD-L1 Immunotherapy Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa PD-1/PD-L1 Immunotherapy Revenue Market Share by Country (2016-2026)
Figure 75. Turkey PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
